Breakthrough Peptide Technology
Hybridtides® are a new class of drug candidates that deliver unique product profiles.
Preclinical Development
Longevity Biotech has multiple preclinical programs in development all based on the Hybridtide® core technology.
PipelineOral Peptide Delivery
Hybridtides® demonstrate robust durability in a variety of biological matrices. Absorption parameters are optimized via our proprietary databases.
Artistan Biology®
The unique composition of Hybridtides® (natural and non-natural amino acids) enables 'fine-tuning' of intracellular signal cascades. In other words, Hybridtides® demonstrate signal bias.
0
Peer Reviewed Papers
0
Citations
0
Patents
0
Preclinical Programs
0
Purpose
Contact Us
Info@LongevityBiotech.com
Office
600 South 43rd Street
Philadelphia, PA 19104
Phone
215.689.1042
Developing breakthrough therapeutics based on the Hybridtide® peptide scaffold
Platform Collaboration
Hybridtide Optimization Toolkit
If your preclinical peptide program requires demonstrated market leading stability in any biological environment - without compromising functionality - contact us, Hybridtides® can deliver your product profile.
Oral Peptide Platform
Formulation alone is not sufficient for commercial success, API's require a combination of stability, solubility and absorption. Our team can evaluate your program across these critical parameters (in vitro and in vivo) and can help optimize your program along these critical dimensions for oral delivery.